Malene Plejdrup Hansen, Sigurd Høye, Katarina Hedin
{"title":"Antibiotic treatment recommendations for acute respiratory tract infections in Scandinavian general practices-time for harmonization?","authors":"Malene Plejdrup Hansen, Sigurd Høye, Katarina Hedin","doi":"10.1080/02813432.2024.2422441","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>During recent years, the world-including Scandinavia-has experienced significant challenges with shortages of antibiotics. In Scandinavia, phenoxymethylpenicillin is recommended as first-line antibiotic treatment for most acute respiratory tract infections (ARTIs). However, the Scandinavian countries each constitute rather small markets for phenoxymethylpenicillin. The aim of this discussion paper is to enlighten the differences in Scandinavian ARTI antibiotic treatment recommendations. This information is fundamental for exploring the potential of harmonizing treatment recommendations in Denmark, Norway and Sweden-to help ensure sufficient future supply of phenoxymethylpenicillin.</p><p><strong>Methods: </strong>Information from national ARTI antibiotic treatment recommendations from respectively Denmark, Norway and Sweden has been collated.</p><p><strong>Results: </strong>Several discrepancies exist in recommendations. Adult dosage varies from a minimum of 660 mg x 4 (Denmark) to a maximum of 2000 mg × 3 (Sweden). Within Norway and Sweden, variations in recommended dosage also exist between the different types of ARTIs. A main challenge is that the tablet strengths recommended, and available on the market in the three countries, differs.Also, antibiotic treatment durations vary significantly between countries and infections treated-from five to 10 days of treatment.</p><p><strong>Conclusion: </strong>In the capacity of a well-established network for antibiotic stewardship, we have enlightened the differences in Scandinavian ARTI antibiotic treatment recommendations. This paper is the first step moving forward to scrutinizing the potential for harmonizing recommendations for Denmark, Norway and Sweden-to help ensure continued supply of phenoxymethylpenicillin for use within the Scandinavian countries.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02813432.2024.2422441","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: During recent years, the world-including Scandinavia-has experienced significant challenges with shortages of antibiotics. In Scandinavia, phenoxymethylpenicillin is recommended as first-line antibiotic treatment for most acute respiratory tract infections (ARTIs). However, the Scandinavian countries each constitute rather small markets for phenoxymethylpenicillin. The aim of this discussion paper is to enlighten the differences in Scandinavian ARTI antibiotic treatment recommendations. This information is fundamental for exploring the potential of harmonizing treatment recommendations in Denmark, Norway and Sweden-to help ensure sufficient future supply of phenoxymethylpenicillin.
Methods: Information from national ARTI antibiotic treatment recommendations from respectively Denmark, Norway and Sweden has been collated.
Results: Several discrepancies exist in recommendations. Adult dosage varies from a minimum of 660 mg x 4 (Denmark) to a maximum of 2000 mg × 3 (Sweden). Within Norway and Sweden, variations in recommended dosage also exist between the different types of ARTIs. A main challenge is that the tablet strengths recommended, and available on the market in the three countries, differs.Also, antibiotic treatment durations vary significantly between countries and infections treated-from five to 10 days of treatment.
Conclusion: In the capacity of a well-established network for antibiotic stewardship, we have enlightened the differences in Scandinavian ARTI antibiotic treatment recommendations. This paper is the first step moving forward to scrutinizing the potential for harmonizing recommendations for Denmark, Norway and Sweden-to help ensure continued supply of phenoxymethylpenicillin for use within the Scandinavian countries.
导言：近年来，包括斯堪的纳维亚半岛在内的世界各国都经历了抗生素短缺的严峻挑战。在斯堪的纳维亚半岛，苯氧青霉素被推荐为治疗大多数急性呼吸道感染（ARTI）的一线抗生素。然而，斯堪的纳维亚各国的苯氧青霉素市场都相当小。本讨论文件旨在说明斯堪的纳维亚半岛 ARTI 抗生素治疗建议的差异。这些信息对于探索统一丹麦、挪威和瑞典治疗建议的可能性至关重要，有助于确保未来苯氧青霉素的充足供应：方法：整理了丹麦、挪威和瑞典三国 ARTI 抗生素治疗建议中的信息：结果：建议中存在一些差异。成人剂量最低为 660 毫克 x 4（丹麦），最高为 2000 毫克 x 3（瑞典）。在挪威和瑞典，不同类型的ARTI在推荐剂量上也存在差异。此外，不同国家和不同感染类型的抗生素治疗时间也有很大差异--从五天到十天不等：通过抗生素监管网络，我们发现了斯堪的纳维亚 ARTI 抗生素治疗建议的差异。本文是研究统一丹麦、挪威和瑞典建议的可能性的第一步，有助于确保斯堪的纳维亚国家持续供应苯氧青霉素。
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
